Valuation : Actinogen Medical Limited

Market Cap 197M 142M 122M 115M 105M 197M 13.42B 1.36B 528M 6.88B 534M 522M 22.17B P/E 2027 *
-
P/E 2028 * -530x
Enterprise Value 197M 142M 122M 115M 105M 197M 13.42B 1.36B 528M 6.88B 534M 522M 22.17B EV / Sales 2027 *
5.12x
EV / Sales 2028 * -
Free-Float
83.36%
Yield 2027 *
-
Yield 2028 * -

Last Transcript : Actinogen Medical Limited

1 day+9.43%
1 week+34.88%
Current month+34.88%
1 month+38.10%
3 months+65.71%
6 months+41.46%
Current year-4.92%
1 week 0.04
Extreme 0.041
0.06
1 month 0.04
Extreme 0.041
0.06
Current year 0.03
Extreme 0.031
0.07
1 year 0.03
Extreme 0.026
0.07
3 years 0.01
Extreme 0.014999
0.1
5 years 0.01
Extreme 0.014999
0.2
10 years 0.01
Extreme 0.007
0.2
Manager TitleAgeSince
Chief Executive Officer 66 2021-03-14
Director of Finance/CFO - 2024-02-04
Chief Tech/Sci/R&D Officer 73 2023-01-31
Director TitleAgeSince
Chairman 70 2017-02-28
Director/Board Member 75 2017-11-30
Director/Board Member 70 2019-04-03
Date Insider Type Main position Quantity % Market Cap. Importance
8/28/26 Exercice

Founder

-275,331 0.0074%
8/28/26 Exercice

Director

-307,269 0.0083%
8/28/26 Exercice

Director

307,269 0.0083%
Change 5-day change 1-year change 3-year change Capi.($)
+9.43%+34.88%+114.81%+132.00% 142M
-1.79%-2.27%+43.23%+99.78% 67.98B
-2.06%-0.18%+39.67%+85.24% 64.94B
-0.31%+6.54%-12.96%+377.83% 27.58B
+0.86%+1.65%-7.74%-13.58% 26.06B
-0.45%+0.12%+25.45%+16.85% 25.74B
-1.46%+0.42%+23.61%-16.76% 20.09B
-2.96%-15.21%+216.20%+375.70% 17.16B
+0.65%-1.05%-6.55%+551.66% 14.92B
-0.20%+8.37%+55.78%+165.57% 14.62B
Average +0.15%+2.28%+49.15%+177.43% 27.92B
Weighted average by Cap. -1.18%+0.19%+37.71%+141.81%

Financials

2027 *2028 *
Net sales 38.5M 27.75M 23.88M 22.47M 20.52M 38.4M 2.62B 265M 103M 1.34B 104M 102M 4.33B -
Net income -700K -505K -434K -409K -373K -698K -47.64M -4.83M -1.87M -24.44M -1.89M -1.85M -78.74M -49.6M -35.75M -30.77M -28.95M -26.44M -49.47M -3.38B -342M -133M -1.73B -134M -131M -5.58B
Net Debt - -
Logo Actinogen Medical Limited
Actinogen Medical Limited is an Australia-based biotechnology company. The Company is engaged in the development of a therapy for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol. The Company is engaged in the development of its lead compound, Xanamem, as a therapy for Alzheimer’s Disease, Major Depressive Disorder, Fragile X Syndrome, and other neurological diseases where reducing cortisol inside brain cells could have a positive impact. Xanamem’s mechanism is to control elevated levels of cortisol (stress hormone) in the brain through the inhibition of the cortisol synthesis enzyme, 11B-HSD1, without affecting production of cortisol by the adrenal glands, which is essential for the body’s normal functioning. Xanamem is a once-a-day pill designed to deliver high levels of cortisol control in key areas of the brain related to Alzheimer’s and other diseases such as the hippocampus and frontal cortex.
Employees
6
Date Price Change Volume
26-09-07 A$0.0580 +9.43% 17,831,080
26-09-04 A$0.0530 +10.42% 11,923,282
26-09-03 A$0.0480 +11.63% 19,535,652
26-09-02 A$0.0430 +4.88% 3,371,727
26-09-01 A$0.0410 -4.65% 4,451,841
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
0.0530AUD
Average target price
0.0800AUD
Spread / Average Target
+50.94%

Annual profits - Rate of surprise

40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!